<DOC>
	<DOCNO>NCT00336895</DOCNO>
	<brief_summary>The objective study determine tolerability safety Myfortic liver transplant patient . Patients receive CellCept GI side effect CellCept discontinue change Myfortic ( Myfortic new drug similar CellCept , except enteric-coated ) . Our hypothesis Myfortic le GI side effect , therefore , tolerate well CellCept also Myfortic comparable effectiveness CellCept .</brief_summary>
	<brief_title>Conversion CellCept Myfortic : A Prospective Study Liver Transplant Recipients</brief_title>
	<detailed_description>This prospective , single center , open-label , safety tolerability study use Myfortic liver transplantation . Adult liver transplant patient experience GI symptom ( nausea , vomit , diarrhea , abdominal discomfort/pain , dyspepsia ) attributable CellCept eligible enter study . CellCept discontinue replace Myfortic . The duration study 3 month , time , assess incidence severity GI adverse event , incidence severity bone marrow suppression ( leukopenia ) , incidence cytomegalovirus ( CMV ) infection disease patient receive Myfortic .</detailed_description>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>ALL patient adult liver transplant recipient , male female , 1880 year age Patients currently receive tacrolimus cyclosporine without corticosteroid part immunosuppressive regimen Patients must receive CellCept must attributable G.I . symptom ( nausea , vomit , diarrhea , abdominal discomfort/pain , dyspepsia ) Patients must 30 day posttransplant eligible Females childbearing potential must negative serum pregnancy test prior inclusion period Multiorgan transplant patient HIV positive patient . Livingrelated liver transplant recipient Pregnant patient Patients history extrahepatic malignancy within last five year , except excise squamous basal cell carcinoma skin Patients thrombocytopenia ( &lt; 50,000/mm3 ) , absolute neutrophil count &lt; 1,000/mm3 and/or leukocytopenia ( &lt; 2,000/mm3 ) , and/or hemoglobin &lt; 7.0 g/dL prior enrollment Patients G.I . clinical problem time enrollment ( e.g . CMV infection disease , C. difficile colitis , active peptic ulcer disease , gastroenteritis , inflammatory bowel disease ) Presence clinically significant infection require continue therapy uncontrolled diabetes mellitus Evidence drug and/or alcohol abuse Decisionally impaired subject medically mentally capable provide consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Liver transplantation</keyword>
	<keyword>mycophenolate mofetil</keyword>
	<keyword>gastrointestinal</keyword>
	<keyword>adverse effect</keyword>
</DOC>